Cellular Repair & Recovery
KLOW
KLOW
KLOW — BPC-157 / GHK-Cu / TB-500 / KPV blend
Research context
KLOW combines four compounds with distinct reported mechanisms: BPC-157 in angiogenic signalling, GHK-Cu in matrix and gene expression, TB-500 in actin sequestration, and KPV in NF-κB pathway modulation. Each component is characterised independently in the published literature; the blend itself has not been separately characterised.
Common assays: Component identity by LC-MS · Purity per component · Collagen synthesis quantification
Specification
| Designation | KLOW |
|---|---|
| Full name | KLOW — BPC-157 / GHK-Cu / TB-500 / KPV blend |
| Components | BPC-157 · GHK-Cu · TB-500 · KPV |
| Formats | 10 mL Vial |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C, protected from light. Reconstituted: 2–8 °C. |
| Current lot | BGTK1511VAS0426 → |
Common questions
How is a four-component blend verified analytically?
Chromatographic separation must resolve all four peaks for individual quantification, with mass confirmation for each. The published lot record reports every component separately, with a measured content figure for each against its label claim.
Same pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
BPC-157 / TB-500
Peptide blend
A prepared blend of the two most extensively studied compounds in the repair signalling literature.